An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2.
This study was designed to answer to two distinct questions. Firstly, is it possible to reproduce clinical signs of acute bovine virus diarrhoea virus (BVDV) type 2 infection including signs of haemorrhagic disease under experimental conditions in cattle at 20 weeks of age? Secondly, what is the extent of the protection afforded by vaccination with an inactivated BVDV type 1 vaccine against BVDV type 2 infection? Calves were vaccinated at 12 and 16 weeks of age with a commercially available inactivated BVDV type 1 vaccine (Bovilis BVD). At 20 weeks they were challenge infected with BVDV type 2 virus together with unvaccinated control calves. The unvaccinated animals developed typical signs of respiratory disease, diarrhoea with erosions and haemorrhages along the whole length gastro-intestinal tract, and depletion of lymphocytes in lymphatic organs. These signs were either absent or markedly less severe in the vaccinated animals. The beneficial effects of vaccination were most striking in the haematological parameters thrombocytopenia and leukopenia. It can be concluded that vaccination with Bovilis BVD affords cross-protection against clinical effects of a challenge-infection with heterologous type 2 BVDV.
Makoschey
B
B
Department of Virological R&D, Intervet International B.V., P.O. Box 31, 5830 AA, Boxmeer, The Netherlands.
Janssen
M G
MG
Vrijenhoek
M P
MP
Korsten
J H
JH
Marel
P
P
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000097:blood / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral / Q000145:classification* / Q000276:immunology* / Q000302:isolation & purification; D030242:Diarrhea Virus 2, Bovine Viral / Q000145:classification* / Q000276:immunology* / Q000302:isolation & purification; D009500:Neutralization Tests; D010581:Peyer's Patches / Q000473:pathology; D010976:Platelet Count; D013950:Thymus Gland / Q000473:pathology; D015164:Vaccines, Inactivated / Q000494:pharmacology; D014765:Viral Vaccines / Q000494:pharmacology*; D014766:Viremia / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines